AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15789977 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush PRO
Number of subjects: 20
Study 15789977 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B CrossAction
Number of subjects: 20
Study 11169936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2 on Day 1) plus Vinorelbine (25 mg/m2 on Days 1 and 8, every 3 weeks for a minimum of 3 cycles)
Number of subjects: 36
Study 11169936 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2/week for a minimum of 9 weeks)
Number of subjects: 36
Study 11169936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 36
Study 11169936 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine alone
Number of subjects: 36
Study 9764992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright basal ganglia signal intensity observed in patients
Number of subjects: 6
Study 9764992 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric evaluation and psychometric tests
Number of subjects: 6
Study 9764992 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial ammonia levels
Number of subjects: 6
Study 9764992 — intervention group
Group type: COMPARATOR
Intervention: Serum manganese concentrations
Number of subjects: 6
Study 7909098 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life support (American Heart Association guidelines) followed by intensive care to a standardised protocol
Number of subjects: 262
Study 7909098 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow and Glasgow‐Pittsburgh coma scores and their constituent signs
Number of subjects: 262
Study 7909098 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of motor response to pain
Number of subjects: 262
Study 3413203 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 52
Study 3413203 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 52
Study 3413203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30195219 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based gait-slip training (8 repeated slips)
Number of subjects: 43
Study 30195219 — intervention group
Group type: COMPARATOR
Intervention: Normal walking trials on the treadmill (control group)
Number of subjects: 43
Study 28637494 — intervention group
Group type: EXPERIMENTAL
Intervention: Euiiyin-tang
Number of subjects: 160
Study 28637494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26275653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris extract (CVE) 1800 mg/day
Number of subjects: 92
Study 26275653 — intervention group
Group type: COMPARATOR
Intervention: Standard antidepressant therapy alone (Control)
Number of subjects: 92
Study 23219636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, high-repetition medical exercise therapy
Number of subjects: 42
Study 23219636 — intervention group
Group type: COMPARATOR
Intervention: Low-dose, low-repetition exercise therapy
Number of subjects: 42
Study 21986283 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 1.0 mg once daily
Number of subjects: 524
Study 21986283 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice daily
Number of subjects: 524
Study 21986283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 21986283 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of LCI699
Number of subjects: 524
Study 21986283 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 524
Study 18712591 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of social support
Number of subjects: 77
Study 18712591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of optimism
Number of subjects: 77
Study 18712591 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of optimism
Number of subjects: 77
Study 17326594 — intervention group
Group type: EXPERIMENTAL
Intervention: AVINZA (morphine sulfate extended-release capsules) once a day
Number of subjects: 392
Study 17326594 — intervention group
Group type: COMPARATOR
Intervention: OxyContin (oxycodone controlled-release tablets) twice a day
Number of subjects: 392
Study 12718385 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (30 mg)
Number of subjects: 63
Study 12718385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg)
Number of subjects: 63
Study 12718385 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 63
Study 12718385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 63
Study 10900630 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 32
Study 10900630 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 32
Study 9548208 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg daily)
Number of subjects: 28
Study 9548208 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg daily)
Number of subjects: 28
Study 9548208 — intervention group
Group type: COMPARATOR
Intervention: Captopril/Enalapril
Number of subjects: 28
Study 1606094 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg intravenous metoclopramide
Number of subjects: 42
Study 1606094 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study 1606094 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 42
Study 6464702 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples positive for pathogenic bacteria (Haemophilus, pneumococci)
Number of subjects: 193
Study 6464702 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples with nonpathogens
Number of subjects: 193
Study 6464702 — intervention group
Group type: EXPERIMENTAL
Intervention: Large mastoid air cell systems
Number of subjects: 193
Study 6464702 — intervention group
Group type: EXPERIMENTAL
Intervention: Destruction of cell walls
Number of subjects: 193
Study 6464702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosis
Number of subjects: 193
Study 31164067 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 hours of therapy
Number of subjects: 41
Study 31164067 — intervention group
Group type: COMPARATOR
Intervention: 0 hours of therapy
Number of subjects: 41
Study 31164067 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 hours of therapy
Number of subjects: 41
Study 31164067 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of therapy
Number of subjects: 41
Study 31164067 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages
Number of subjects: 41
Study 31164067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test
Number of subjects: 41
Study 28326598 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion meditation (CM) group
Number of subjects: 59
Study 28326598 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 59
Study 26890016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Barrage Stimulation (SBS)
Number of subjects: 10
Study 26890016 — intervention group
Group type: COMPARATOR
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 10
Study 26890016 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS
Number of subjects: 10
Study 26890016 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 10
Study 25194106 — intervention group
Group type: EXPERIMENTAL
Intervention: 540 mL bladder-filling protocol
Number of subjects: 110
Study 25194106 — intervention group
Group type: COMPARATOR
Intervention: 1080 mL bladder-filling protocol
Number of subjects: 110
Study 20385892 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 1 mg 3 times daily
Number of subjects: 23
Study 20385892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16163745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at baseline
Number of subjects: 318
Study 16163745 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at baseline
Number of subjects: 318
Study 16163745 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 318
Study 16163745 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, physical disability, social functioning
Number of subjects: 318
Study 11408832 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 15
Study 11408832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9741812 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed hardware unit allowing adjustable delay of data acquisition after stimuli
Number of subjects: 0
Study 9741812 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed software for fast analogue-to-digital conversion (ADC) during data acquisition
Number of subjects: 0
Study 9741812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vickers Medical Mystro electromyograph
Number of subjects: 0
Study 8035933 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg or 800 mg)
Number of subjects: 10
Study 8035933 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa (150 mg) plus placebo
Number of subjects: 10
Study 8035933 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (150 mg) plus entacapone (400 mg or 800 mg)
Number of subjects: 10
Study 2564109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-fluorouracil and mitomycin C with or without induction course of 5-fluorouracil, vincristine, cyclophosphamide, and methotrexate)
Number of subjects: 411
Study 2564109 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 411
Study 4772727 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzhexol (8 mg/day)
Number of subjects: 0
Study 4772727 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic withdrawal
Number of subjects: 0
Study 29216779 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing essential oils and ethyl lauroyl arginate
Number of subjects: 0
Study 29216779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (21.6% hydro-alcohol solution)
Number of subjects: 0
Study 29216779 — intervention group
Group type: COMPARATOR
Intervention: Negative control (sterile water)
Number of subjects: 0
Study 27475733 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted heparin regimen
Number of subjects: 60
Study 27475733 — intervention group
Group type: COMPARATOR
Intervention: Traditional heparin regimen
Number of subjects: 60
Study 24005444 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP therapy
Number of subjects: 90
Study 24005444 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including physical exercise)
Number of subjects: 90
Study 22386009 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned nursing consultations
Number of subjects: 287
Study 22386009 — intervention group
Group type: COMPARATOR
Intervention: Planned rheumatologist's consultations
Number of subjects: 287
Study 22386009 — intervention group
Group type: COMPARATOR
Intervention: Shared care model without planned consultations
Number of subjects: 287
Study 20150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (n=30)
Number of subjects: 63
Study 20150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (n=33)
Number of subjects: 63
Study 17971121 — intervention group
Group type: EXPERIMENTAL
Intervention: Two axial grooves added to the crown preparation
Number of subjects: 30
Study 17971121 — intervention group
Group type: COMPARATOR
Intervention: Recementation of crowns
Number of subjects: 30
Study 17971121 — intervention group
Group type: COMPARATOR
Intervention: One axial groove added to the crown preparation
Number of subjects: 30
Study 16045805 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based search of randomised trials
Number of subjects: 31
Study 12810695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin-2 (IL-2) at a dosage of 600,000 U/kg every 8 hours on days 1 to 5 and days 15 to 19 (maximum 28 doses)
Number of subjects: 69
Study 12810695 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 69
Study 12810695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin-2 (IL-2)
Number of subjects: 69
Study 10579620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical tenaculum placement during embryo transfer (ET)
Number of subjects: 10
Study 10579620 — intervention group
Group type: COMPARATOR
Intervention: No tenaculum placement during embryo transfer (ET)
Number of subjects: 10
Study 8568910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sources of hydroquinone (arbutin and free HQ) from foods such as wheat products, pears, coffee, tea, red wine, and broccoli.
Number of subjects: 0
Study 8568910 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking four cigarettes in approximately 30 minutes.
Number of subjects: 0
Study 1880721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (fed condition)
Number of subjects: 12
Study 1880721 — intervention group
Group type: COMPARATOR
Intervention: Fasted condition (control)
Number of subjects: 12
Study 7093095 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 12
Study 7093095 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 7093095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31072716 — intervention group
Group type: COMPARATOR
Intervention: CIS
Number of subjects: 21
Study 31072716 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSA
Number of subjects: 21
Study 31072716 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 21
Study 29924038 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 21
Study 29924038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS (channeled blade-type videolaryngoscope)
Number of subjects: 21
Study 29924038 — intervention group
Group type: COMPARATOR
Intervention: McGRATH videolaryngoscope (non-channeled blade type)
Number of subjects: 21
Study 26911438 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Glove (SG) group
Number of subjects: 46
Study 26911438 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention (CON) group
Number of subjects: 46
Study 26464863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb supplementation (350mg, thrice daily for 12 weeks)
Number of subjects: 0
Study 26464863 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 0
Study 22905352 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (n=34)
Number of subjects: 68
Study 22905352 — intervention group
Group type: COMPARATOR
Intervention: Placebo needling (n=34)
Number of subjects: 68
Study 20674901 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination (IUI)
Number of subjects: 160
Study 20674901 — intervention group
Group type: COMPARATOR
Intervention: Double intrauterine insemination (IUI)
Number of subjects: 160
Study 17403173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid 10 mg 3 times a week immediately after every dialysis session
Number of subjects: 186
Study 17403173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 17403173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid
Number of subjects: 186
Study 15684203 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 8518
Study 15684203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 8518
Study 11972407 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 9837
Study 11972407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9837
Study 10214599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video 'Telling the Story ... To Live is God's Will'
Number of subjects: 70
Study 10214599 — intervention group
Group type: COMPARATOR
Intervention: Control video 'Colorectal Cancer: The Cancer No One Talks About'
Number of subjects: 70
Study 10214599 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Intervention and Control)
Number of subjects: 70
Study 7883120 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid substitutions in hexokinase II among patients with NIDDM
Number of subjects: 112
Study 7883120 — intervention group
Group type: COMPARATOR
Intervention: Control group (97 subjects with normal glucose tolerance)
Number of subjects: 112
Study 2095342 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 micrograms
Number of subjects: 12
Study 2095342 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 12
Study 2095342 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 300 micrograms
Number of subjects: 12
Study 2095342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2095342 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of Salbutamol
Number of subjects: 12
Study 873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabid-Organon (standard therapeutic doses)
Number of subjects: 12
Study 31234844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nitrogen-containing bisphosphonates
Number of subjects: 0
Study 31234844 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27815860 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Number of subjects: 57
Study 27815860 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 57
Study 25996468 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial‐Oral Tract Therapy (F.O.T.T.)
Number of subjects: 119
Study 25996468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)
Number of subjects: 119
Study 25996468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 23216760 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted (BFR) exercise
Number of subjects: 9
Study 23216760 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without BFR
Number of subjects: 9
Study 21670398 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW diet
Number of subjects: 49
Study 21670398 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH diet
Number of subjects: 49
Study 19367397 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5,000 Units twice daily
Number of subjects: 1994
Study 19367397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg per day
Number of subjects: 1994
Study 19367397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1994
Study 16492813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 56
Study 15334697 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 70
Study 15334697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ap‐237
Number of subjects: 70
Study 15334697 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 70
Study 15334697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 70
Study 11198726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 401
Study 11198726 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg three times daily for 7 days)
Number of subjects: 401
Study 11198726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 401
Study 11198726 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 401
Study 9129086 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, zalcitabine, and saquinavir (exact dosages and duration not specified)
Number of subjects: 9
Study 7960187 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR IgG test result > 40%
Number of subjects: 1189
Study 7960187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower MAR IgG test results and majority of MAR IgA-positive patients
Number of subjects: 1189
Study 7960187 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MAR results
Number of subjects: 1189
Study 2956200 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg nifedipine administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Number of subjects: 12
Study 2956200 — intervention group
Group type: COMPARATOR
Intervention: Solvent administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Number of subjects: 12
Study 2956200 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg nifedipine administered intracoronarily just before the second transluminal occlusion.
Number of subjects: 12
Study 2956200 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine group during the second transluminal occlusion.
Number of subjects: 12
Study 2956200 — intervention group
Group type: COMPARATOR
Intervention: Solvent group during the second transluminal occlusion.
Number of subjects: 12
Study 30586723 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 6979
Study 30586723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6979
Study 30138233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 38
Study 30138233 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 38
Study 30138233 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with PD
Number of subjects: 38
Study 26111347 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence enhancement intervention
Number of subjects: 138
Study 26111347 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 23895391 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral cues indicating no specific temporal position of the comparison stimulus
Number of subjects: 0
Study 23895391 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid cues indicating the temporal position of the comparison stimulus
Number of subjects: 0